Trial: MEDI5752 in Combination With Carboplati…

Trial Details

Sponsor: AstraZeneca (industry)

Phase: 3

Start date: Nov. 9, 2023

Planned enrollment: 825

Trial ID: NCT06097728

More trial details at ClinicalTrials.gov

Show Summary from Sponsor

Investigational Drug AI Analysis

Show for: Volrustomig (MEDI5752, PD-1/CTLA-4 DuetMab, MEDI-5752)

Overview

Volrustomig (MEDI5752) is an investigational, humanized, monovalent bispecific IgG1 antibody that targets PD‑1 and CTLA‑4. It is being studied across multiple tumor types, including renal cell carcinoma (RCC), non–small cell lung cancer (NSCLC), pleural mesothelioma, hepatobiliary cancers, and head and neck cancer, in phases 1–3. Early clinical data show antitumor activity, with ongoing efforts to optimize dose to balance efficacy and immune‑related toxicities. (aacrjournals.org)

Mechanism of action

Volrustomig binds PD‑1 and CTLA‑4 with a “DuetMab” monovalent bispecific format engineered to fully block PD‑1 while preferentially inhibiting CTLA‑4 on activated PD‑1–positive T cells within tumors. This design enhances CTLA‑4 engagement in the tumor microenvironment and reduces activity on PD‑1–negative peripheral T cells. Tethering CTLA‑4 to PD‑1 also drives rapid internalization and degradation of PD‑1, providing a distinct mechanism from conventional separate PD‑1 and CTLA‑4 monoclonal antibodies. The Fc region is engineered to reduce effector function. (aacrjournals.org)

Efficacy

Advanced clear‑cell RCC (first‑line, monotherapy): In a phase 1 expansion (NCT03530397), volrustomig 1,500 mg Q3W produced an ORR of 38.5% in all expansion patients (n=26) and 58.3% in the first‑line ccRCC subset (n=12); median duration of response, PFS, and OS were not reached at 14.6 months’ follow‑up in the first‑line subset. Subsequent first‑line cohorts tested lower fixed doses. At ESMO 2023, ORR was 46.9% with 750 mg (n=32) and 45.5% with 500 mg (n=33); complete responses 9.4% and 6.1%, respectively; median PFS 11.1 and 9.9 months. (ascopubs.org)
Metastatic non‑squamous NSCLC (first‑line, with chemotherapy): In ESMO 2022 LBA56 (phase 1b/2, NCT03530397), volrustomig 1,500 mg + carboplatin/pemetrexed improved median PFS (15.1 vs 8.9 mo), DOR (20.5 vs 9.9 mo), and OS (not reached vs 16.5 mo) versus pembrolizumab + chemotherapy in a small randomized signal‑finding cohort (n=41). A separate single‑arm cohort using 750 mg + chemotherapy showed emerging ORR 44% overall and 48% in PD‑L1 <1% with improved tolerability at ~3.9 months’ follow‑up. A phase 3 trial (eVOLVE‑Lung02) is comparing volrustomig + chemotherapy vs pembrolizumab + chemotherapy in PD‑L1 <50% mNSCLC. (oncologypro.esmo.org)
Ongoing phase 3 programs: Volrustomig + carboplatin/pemetrexed is being compared against platinum/pemetrexed or nivolumab/ipilimumab in unresectable pleural mesothelioma; additional phase 3 evaluation is underway as consolidation after chemoradiotherapy in locally advanced head and neck squamous cell carcinoma. Results are pending. (mayo.edu)
Other tumor settings under study: Master protocols include combinations in hepatocellular and biliary tract cancers (e.g., volrustomig ± bevacizumab or lenvatinib; volrustomig + gemcitabine/cisplatin). RCC combinations with VEGF‑TKIs (e.g., lenvatinib/axitinib) are also in early‑phase evaluation. (mskcc.org)

Safety

Class‑consistent immune‑related adverse events (irAEs) occur and increase with higher dosing/intensity of CTLA‑4 engagement. In RCC expansion at 1,500 mg Q3W, grade 3–4 treatment‑related AEs occurred in 74.1% with discontinuations in 70.4%; hepatotoxicity was a common reason for discontinuation. In the dose‑escalation/expansion RCC cohorts overall, grade 5 TRAEs occurred in 1 patient per cohort. (ascopubs.org)
In NSCLC (ESMO 2022), volrustomig 1,500 mg + chemotherapy had grade ≥3 TRAEs and discontinuations of 70% each; lowering to 750 mg + chemotherapy reduced grade ≥3 TRAEs to 32% and discontinuations to 20%, while maintaining antitumor activity signals. (oncologypro.esmo.org)
Across first‑line RCC mini‑oral cohorts (ESMO 2023), grade 3–4 immune‑related AEs were more frequent at 750 mg than 500 mg (46.9% vs 24.2%), but most non‑endocrine irAEs resolved and about half did not require steroids; overall disease control remained high. (oncologypro.esmo.org)

TrialFetch AI Analysis

Goal: Evaluate whether adding volrustomig (MEDI5752) to carboplatin plus pemetrexed improves survival and clinical outcomes compared with current first-line standards—platinum plus pemetrexed or nivolumab plus ipilimumab—in unresectable pleural mesothelioma.

Patients: Adults ≥18 years with histologically confirmed unresectable pleural mesothelioma (epithelioid or non-epithelioid), measurable disease by modified RECIST 1.1, ECOG 0–1, and adequate organ function. Key exclusions include active or prior significant autoimmune/inflammatory disease, uncontrolled infections (including uncontrolled HBV/HCV/HIV, TB), another active malignancy with limited exceptions, untreated or progressive CNS metastases, and concurrent anticancer therapies.

Design: Global, multicenter, phase III, randomized, open-label study with 1:1 allocation to experimental therapy versus investigator’s choice control, stratified by histology. Planned enrollment is 825 participants. Primary intent is treatment with overall survival as the primary endpoint; follow-up up to approximately 61 months.

Treatments: Experimental: Volrustomig plus carboplatin and pemetrexed. Volrustomig (MEDI5752) is a monovalent bispecific antibody targeting PD-1 and CTLA-4, designed to fully inhibit PD-1 and preferentially inhibit CTLA-4 on activated PD-1–positive T cells in tumors, potentially enhancing intratumoral activity while reducing peripheral toxicity versus separate checkpoint antibodies. The bispecific format promotes PD-1 internalization and degradation. Early-phase studies in solid tumors, notably first-line renal cell carcinoma, showed objective response rates around 45% to 48% at doses of 500–750 mg every 3 weeks, with dose-dependent immune-related toxicity higher at ≥1500 mg; development focuses on sub-1500 mg dosing to balance efficacy and safety. Control: Investigator’s choice of standard of care—platinum (carboplatin or cisplatin) plus pemetrexed for epithelioid histology, or nivolumab plus ipilimumab; for non-epithelioid histology, nivolumab plus ipilimumab is mandated.

Outcomes: Primary: Overall survival. Secondary: Overall survival (additional analyses), progression-free survival by mRECIST 1.1 and/or RECIST 1.1, landmark OS (12, 18, 24, 36 months), landmark PFS (6, 12, 18, 24 months), overall response rate, duration of response, PFS2, patient-reported outcomes including physical function (PROMIS PF SF 8c), disease-related symptoms (EORTC IL305 and PRO-CTCAE items), role functioning and global health/HRQoL (EORTC QLQ-C30 subscales), safety by CTCAE v5.0, immunogenicity (anti-drug antibodies), and volrustomig pharmacokinetics (AUC, Cmax, Tmax).

Burden on patient: Moderate. As a phase III study with intravenous therapies, participants will undergo regular clinic visits for infusions, safety labs, and imaging at intervals typical for first-line mesothelioma care. Added burden arises from investigational agent-specific assessments, including immunogenicity sampling and pharmacokinetic timepoints, which increase blood draw frequency, particularly in early cycles. Patient-reported outcome questionnaires at multiple visits add brief time commitments. No mandated additional invasive procedures beyond standard-of-care biopsies are described. Travel and time demands align with standard chemoimmunotherapy schedules, with modest incremental visits for PK/ADA collections and study assessments over approximately 5 years of follow-up.

Last updated: Oct 2025

Eligibility

Show Criteria

Sites (180)

Sort by distance to:

Research Site

Clayton, 3168, Australia

No email / No phone

Status: Recruiting

Research Site

Westmead, 2145, Australia

No email / No phone

Status: Recruiting

Research Site

Nedlands, 6009, Australia

No email / No phone

Status: Recruiting

Research Site

Melbourne, 3000, Australia

No email / No phone

Status: Recruiting

Research Site

Chermside, 4032, Australia

No email / No phone

Status: Recruiting

Research Site

Antwerp, 2020, Belgium

No email / No phone

Status: Recruiting

Research Site

Anderlecht, 1070, Belgium

No email / No phone

Status: Recruiting

Research Site

Sint-Niklaas, 9100, Belgium

No email / No phone

Status: Recruiting

Research Site

Hasselt, 3500, Belgium

No email / No phone

Status: Recruiting

Research Site

Ghent, 9000, Belgium

No email / No phone

Status: Recruiting

Research Site

Porto Alegre, 91350-200, Brazil

No email / No phone

Status: Recruiting

Research Site

Fortaleza, 60336-045, Brazil

No email / No phone

Status: Recruiting

Research Site

Barretos, 14784-400, Brazil

No email / No phone

Status: Recruiting

Research Site

Rio de Janeiro, 22281-100, Brazil

No email / No phone

Status: Recruiting

Research Site

São Paulo, 01246-000, Brazil

No email / No phone

Status: Recruiting

Research Site

Santo André, 09060-650, Brazil

No email / No phone

Status: Recruiting

Research Site

Edmonton, Alberta, T6G 1Z2, Canada

No email / No phone

Status: Recruiting

Research Site

Ottawa, Ontario, K1H 8L6, Canada

No email / No phone

Status: Recruiting

Research Site

Toronto, Ontario, M5G 1X6, Canada

No email / No phone

Status: Recruiting

Research Site

London, Ontario, N6A 5W9, Canada

No email / No phone

Status: Recruiting

Research Site

Québec, Quebec, G1V 4G5, Canada

No email / No phone

Status: Recruiting

Research Site

Montreal, Quebec, H2X 0C1, Canada

No email / No phone

Status: Recruiting

Research Site

Harbin, 150049, China

No email / No phone

Status: Recruiting

Research Site

Beijing, 100142, China

No email / No phone

Status: Recruiting

Research Site

Beijing, 100210, China

No email / No phone

Status: Recruiting

Research Site

Changsha, 410013, China

No email / No phone

Status: Recruiting

Research Site

Chengdu, 610042, China

No email / No phone

Status: Recruiting

Research Site

Chongqing, 400030, China

No email / No phone

Status: Recruiting

Research Site

Guangzhou, 510100, China

No email / No phone

Status: Recruiting

Research Site

Hangzhou, 310022, China

No email / No phone

Status: Recruiting

Research Site

Kunming, 650118, China

No email / No phone

Status: Recruiting

Research Site

Lanzhou, 730000, China

No email / No phone

Status: Recruiting

Research Site

Ningbo, 315100, China

No email / No phone

Status: Recruiting

Research Site

Qingdao, 266003, China

No email / No phone

Status: Recruiting

Research Site

Shandong, China

No email / No phone

Status: Recruiting

Research Site

Shanghai, 200032, China

No email / No phone

Status: Recruiting

Research Site

Shenyang, 110044, China

No email / No phone

Status: Recruiting

Research Site

Taiyuan, 030000, China

No email / No phone

Status: Recruiting

Research Site

Taiyuan, 030032, China

No email / No phone

Status: Recruiting

Research Site

Tianjin, 300050, China

No email / No phone

Status: Recruiting

Research Site

Tianjin, 300060, China

No email / No phone

Status: Recruiting

Research Site

Wuhan, 430030, China

No email / No phone

Status: Recruiting

Research Site

Xi'an, 710061, China

No email / No phone

Status: Recruiting

Research Site

Zhengzhou, 450008, China

No email / No phone

Status: Recruiting

Research Site

Zhengzhou, 450052, China

No email / No phone

Status: Recruiting

Research Site

Copenhagen, 2100, Denmark

No email / No phone

Status: Recruiting

Research Site

Aarhus N, 8200, Denmark

No email / No phone

Status: Recruiting

Research Site

Lille, 59037, France

No email / No phone

Status: Recruiting

Research Site

Lyon, 69373, France

No email / No phone

Status: Recruiting

Research Site

Marseille, 13015, France

No email / No phone

Status: Recruiting

Research Site

Montpellier, 34298, France

No email / No phone

Status: Recruiting

Research Site

Paris, 75877, France

No email / No phone

Status: Recruiting

Research Site

Rouen, 76031, France

No email / No phone

Status: Recruiting

Research Site

Saint-Herblain, 44800, France

No email / No phone

Status: Recruiting

Research Site

Strasbourg, 67091, France

No email / No phone

Status: Recruiting

Research Site

Toulouse, 31059, France

No email / No phone

Status: Recruiting

Research Site

Brest, 29200, France

No email / No phone

Status: Recruiting

Research Site

Créteil, 94010, France

No email / No phone

Status: Recruiting

Research Site

Le Mans, 72037, France

No email / No phone

Status: Recruiting

Research Site

Cologne, 51109, Germany

No email / No phone

Status: Recruiting

Research Site

Essen, 45122, Germany

No email / No phone

Status: Recruiting

Research Site

Gauting, 82131, Germany

No email / No phone

Status: Recruiting

Research Site

Georgsmarienhütte, 49124, Germany

No email / No phone

Status: Recruiting

Research Site

Großhansdorf, 22927, Germany

No email / No phone

Status: Recruiting

Research Site

Hamburg, 21075, Germany

No email / No phone

Status: Recruiting

Research Site

Heidelberg, 69126, Germany

No email / No phone

Status: Recruiting

Research Site

Kiel, 24105, Germany

No email / No phone

Status: Recruiting

Research Site

Münster, 48153, Germany

No email / No phone

Status: Recruiting

Research Site

Regensburg, 93049, Germany

No email / No phone

Status: Recruiting

Research Site

Berlin, 13125, Germany

No email / No phone

Status: Recruiting

Research Site

Berlin, 14109, Germany

No email / No phone

Status: Recruiting

Research Site

Bochum, 44791, Germany

No email / No phone

Status: Recruiting

Research Site

Varese, 21100, Italy

No email / No phone

Status: Recruiting

Research Site

Alessandria, 15100, Italy

No email / No phone

Status: Recruiting

Research Site

Bari, 70124, Italy

No email / No phone

Status: Recruiting

Research Site

Bergamo, 24125, Italy

No email / No phone

Status: Recruiting

Research Site

Milan, 20141, Italy

No email / No phone

Status: Recruiting

Research Site

Monza, 20052, Italy

No email / No phone

Status: Recruiting

Research Site

Orbassano, 10043, Italy

No email / No phone

Status: Recruiting

Research Site

Padua, 35128, Italy

No email / No phone

Status: Recruiting

Research Site

Parma, 43100, Italy

No email / No phone

Status: Recruiting

Research Site

Rozzano, 20089, Italy

No email / No phone

Status: Recruiting

Research Site

Okayama, 702-8055, Japan

No email / No phone

Status: Recruiting

Research Site

Amagasaki-shi, 660-8550, Japan

No email / No phone

Status: Recruiting

Research Site

Hakodate-shi, 040-8611, Japan

No email / No phone

Status: Recruiting

Research Site

Hiroshima, 734-8551, Japan

No email / No phone

Status: Recruiting

Research Site

Kitaadachi-gun, 362-0806, Japan

No email / No phone

Status: Recruiting

Research Site

Matsuyama, 791-0280, Japan

No email / No phone

Status: Recruiting

Research Site

Kitakyushu-shi, 807-8555, Japan

No email / No phone

Status: Recruiting

Research Site

Nishinomiya-shi, 663-8501, Japan

No email / No phone

Status: Recruiting

Research Site

Ube-shi, 755-0241, Japan

No email / No phone

Status: Recruiting

Research Site

Tokyo, 104-0045, Japan

No email / No phone

Status: Recruiting

Research Site

Osakasayama-shi, 589-8511, Japan

No email / No phone

Status: Recruiting

Research Site

Nagoya, 466-8560, Japan

No email / No phone

Status: Recruiting

Research Site

Rotterdam, 3015 GD, Netherlands

No email / No phone

Status: Recruiting

Research Site

Eindhoven, 5623EJ, Netherlands

No email / No phone

Status: Recruiting

Research Site

Amsterdam, 1066CX, Netherlands

No email / No phone

Status: Recruiting

Research Site

Lørenskog, 1478, Norway

No email / No phone

Status: Recruiting

Research Site

Oslo, 450, Norway

No email / No phone

Status: Recruiting

Research Site

Bystra, 43-360, Poland

No email / No phone

Status: Recruiting

Research Site

Olsztyn, 10-357, Poland

No email / No phone

Status: Recruiting

Research Site

Poznan, 60-569, Poland

No email / No phone

Status: Recruiting

Research Site

Warsaw, 02-781, Poland

No email / No phone

Status: Recruiting

Research Site

Kimberly, 8301, South Africa

No email / No phone

Status: Recruiting

Research Site

Pretoria, 0002, South Africa

No email / No phone

Status: Recruiting

Research Site

Pretoria, 0081, South Africa

No email / No phone

Status: Recruiting

Research Site

Cape Town, 7570, South Africa

No email / No phone

Status: Recruiting

Research Site

eManzimtoti, 4126, South Africa

No email / No phone

Status: Recruiting

Research Site

Johannesburg, 2193, South Africa

No email / No phone

Status: Recruiting

Research Site

Ulsan, 44033, South Korea

No email / No phone

Status: Recruiting

Research Site

Seoul, 06591, South Korea

No email / No phone

Status: Recruiting

Research Site

Seoul, 06351, South Korea

No email / No phone

Status: Recruiting

Research Site

Seoul, 03080, South Korea

No email / No phone

Status: Recruiting

Research Site

Barcelona, 8035, Spain

No email / No phone

Status: Recruiting

Research Site

Oviedo, 33011, Spain

No email / No phone

Status: Recruiting

Research Site

Madrid, 28041, Spain

No email / No phone

Status: Recruiting

Research Site

Barakaldo, 48903, Spain

No email / No phone

Status: Recruiting

Research Site

Fribourg, 1700, Switzerland

No email / No phone

Status: Recruiting

Research Site

Baden, CH-5405, Switzerland

No email / No phone

Status: Recruiting

Research Site

Basel, 4031, Switzerland

No email / No phone

Status: Recruiting

Research Site

Bern, 3010, Switzerland

No email / No phone

Status: Recruiting

Research Site

Sankt Gallen, 9007, Switzerland

No email / No phone

Status: Recruiting

Research Site

Taichung, 40705, Taiwan

No email / No phone

Status: Recruiting

Research Site

Kaohsiung City, 80756, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taipei, 10002, Taiwan

No email / No phone

Status: Recruiting

Research Site

Tainan, 70403, Taiwan

No email / No phone

Status: Recruiting

Research Site

Ankara, 06800, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Izmir, 35110, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Diyarbakır, 21280, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Portsmouth, PO6 3LY, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Newcastle upon Tyne, NE2 4HH, United Kingdom

No email / No phone

Status: Recruiting

Research Site

London, SW3 6JJ, United Kingdom

No email / No phone

Status: Recruiting

Research Site

London, SE1 9RT, United Kingdom

No email / No phone

Status: Recruiting

Research Site

London, NW1 2PG, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Leicester, LE1 5WW, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Leeds, LS9 7TF, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Cambridge, CB20QQ, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Taunton, TA1 5DA, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Manchester, M23 9LT, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Santa Rosa, California, 95403, United States

No email / No phone

Status: Recruiting

Research Site

Aurora, Colorado, 80045, United States

No email / No phone

Status: Recruiting

Research Site

Jacksonville, Florida, 32224, United States

No email / No phone

Status: Recruiting

Research Site

Atlanta, Georgia, 30322, United States

No email / No phone

Status: Recruiting

Research Site

Chicago, Illinois, 60637, United States

No email / No phone

Status: Recruiting

Research Site

Rochester, Minnesota, 55905, United States

No email / No phone

Status: Recruiting

Research Site

St Louis, Missouri, 63110, United States

No email / No phone

Status: Recruiting

Research Site

Commack, New York, 11725, United States

No email / No phone

Status: Recruiting

Research Site

Valhalla, New York, 10595, United States

No email / No phone

Status: Recruiting

Research Site

Columbus, Ohio, 43210, United States

No email / No phone

Status: Recruiting

Research Site

Cleveland, Ohio, 44111, United States

No email / No phone

Status: Recruiting

Research Site

Cleveland, Ohio, 44124, United States

No email / No phone

Status: Recruiting

Research Site

Cleveland, Ohio, 44195, United States

No email / No phone

Status: Recruiting

Research Site

Independence, Ohio, 44131, United States

No email / No phone

Status: Recruiting

Research Site

Portland, Oregon, 97239, United States

No email / No phone

Status: Recruiting

Research Site

Portland, Oregon, 97213, United States

No email / No phone

Status: Recruiting

Research Site

Portland, Oregon, 97225, United States

No email / No phone

Status: Recruiting

Research Site

Philadelphia, Pennsylvania, 19104, United States

No email / No phone

Status: Recruiting

Research Site

Houston, Texas, 77030, United States

No email / No phone

Status: Recruiting

Research Site

Fairfax, Virginia, 22031, United States

No email / No phone

Status: Recruiting

Research Site

Changchun, 130021, China

No email / No phone

Status: Not yet recruiting

Research Site

Taoyuan District, 333, Taiwan

No email / No phone

Status: Not yet recruiting

Research Site

Baltimore, Maryland, 21231, United States

No email / No phone

Status: Not yet recruiting

Research Site

Leuven, 3000, Belgium

No email / No phone

Status: Withdrawn

Research Site

João Pessoa, 58013-140, Brazil

No email / No phone

Status: Withdrawn

Research Site

Hamilton, Ontario, L8V 1C3, Canada

No email / No phone

Status: Withdrawn

Research Site

Guangzhou, 510060, China

No email / No phone

Status: Withdrawn

Research Site

Guangzhou, 510180, China

No email / No phone

Status: Withdrawn

Research Site

Nanchang, 330006, China

No email / No phone

Status: Withdrawn

Research Site

Essen, 45130, Germany

No email / No phone

Status: Withdrawn

Research Site

Rzeszów, 35-241, Poland

No email / No phone

Status: Withdrawn

Research Site

Bydgoszcz, 85-796, Poland

No email / No phone

Status: Withdrawn

Research Site

Polokwane, 0700, South Africa

No email / No phone

Status: Withdrawn

Research Site

Cheongju-si, 28644, South Korea

No email / No phone

Status: Withdrawn

Research Site

Adana, 01060, Turkey (Türkiye)

No email / No phone

Status: Withdrawn

Research Site

Cardiff, Wales, CF5 6NF, United Kingdom

No email / No phone

Status: Withdrawn

Research Site

Phoenix, Arizona, 85054, United States

No email / No phone

Status: Withdrawn

Research Site

Duarte, California, 91010, United States

No email / No phone

Status: Withdrawn

Research Site

East Brunswick, New Jersey, 08816, United States

No email / No phone

Status: Withdrawn

Research Site

Johannesburg, 2013, South Africa

No email / No phone

Status: SUSPENDED

Research Site

Ankara, 06280, Turkey (Türkiye)

No email / No phone

Status: SUSPENDED

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Trial Details

Show Summary from Sponsor

More details:

Investigational Drug AI Analysis

Show for: Volrustomig (MEDI5752, PD-1/CTLA-4 DuetMab, MEDI-5752)

Overview

Mechanism of action

Efficacy

Safety

Further reading

TrialFetch AI Analysis

Eligibility

Show Criteria

Sites (180)

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site